Objective: to determine the nature of the effect of combining atorvastatin with the antioxidant drug ethylmethylhydroxypyridine malate on the lipid profile of patients with coronary heart disease. A pilot randomized clinical trial of 60 patients with coronary artery disease was carried out. The patients were divided into two equal groups. The first group (n = 30) consisted of patients who received basic therapy for coronary artery disease (antiplatelet agents, statins, beta-blockers, antianginal drugs) with a dosage of atorvastatin 20 mg/day. In the second one (n = 30), in addition to the basic drugs with 20 mg/day of atorvastatin, patients received ethylmethylhydroxypyridine malate in tablet form at a dose of 300 mg per day. The patients were comprehensively examined with an assessment of the lipid profile in the blood. With initial hypercholesterolemia in the first group of patients after 60 days of treatment, the level of total cholesterol decreased by 25 % from 6,63 ± 0,33 to 4,95 ± 0,45 mmol/l (p < 0,01), the level of low density lipoprotein cholesterol (LDL cholesterol) decreased by 32 % from 4,31 ± 0,32 to 2,91 ±0,45 (p < 0,05), and the atherogenic coefficient (Сa) decreased by 32 % from 5,06 ± 0,67 to 3,43 ± 0,63 (p > 0,05). In the second group, the level of total cholesterol decreased by 34 % from 6,98 ± 0,50 to 4,58 ± 0,47 mmol/l (p < 0,01), the level of LDL cholesterol decreased by 47 % from 4,53 ± 0,48 to 2,39 ± 0,54 (p < 0,01) and Сa decreased by 47 % from 4,59 ± 0,55 to 2,44 ± 0,39 (p < 0,01). With initially normal values of serum cholesterol (up to 5,0 mmol/l). No significant difference between the comparison groups in the dynamics of treatment was revealed. The synergistic effect of the combination of atorvastatin and the antioxidant drug ethylmethylhydroxypyridine malate on the lipid profile of patients with coronary heart disease has been proven.